ArticleAmerican journal of cancer research2020
Stabilization of oncogenic transcripts by the IGF2BP3/ELAVL1 complex promotes tumorigenicity in colorectal cancer.
Article in American journal of cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 32 citations in OpenAlex.
- Transcriptome-wide splicing analysis reveals HuR-regulated post-transcriptional programs in osteocytes.iScience · 2026Article
- CXCL12 deficiency promotes colorectal cancer progression and reduces anti-PD-L1 immunotherapy efficacy through MDSC regulation.Journal of translational medicine · 2025Article
- IGF2BP3 promotes the proliferation and cisplatin resistance of bladder cancer by enhancing the mRNA stability of CDK6 in an m6A dependent manner.International journal of biological sciences · 2025Article
- IGF2BPs as novel mGenes & diseases · 2024Review
- Recent advances of m6A methylation in skeletal system disease.Journal of translational medicine · 2024Review
- Article
- LncRNA AGAP2 antisense RNA 1 stabilized by insulin-like growth factor 2 mRNA binding protein 3 promotes macrophage M2 polarization in clear cell renal cell carcinoma through regulation of the microRNA-9-5p/THBS2/PI3K-Akt pathway.Cancer cell international · 2023Article
- A TRIM21-based bioPROTAC highlights the therapeutic benefit of HuR degradation.Nature communications · 2023Article
- Optimized infrared photoactivatable ribonucleoside-enhanced crosslinking and immunoprecipitation (IR-PAR-CLIP) protocol identifies novel IGF2BP3-interacting RNAs in colon cancer cells.RNA (New York, N.Y.) · 2023Article
- IGF2BP3 promotes the progression of colorectal cancer and mediates cetuximab resistance by stabilizing EGFR mRNA in an mCell death & disease · 2023Article
- m5C-methylated lncRNA NR_033928 promotes gastric cancer proliferation by stabilizing GLS mRNA to promote glutamine metabolism reprogramming.Cell death & disease · 2023Article
- MIMT1 and LINC01550 are uncharted lncRNAs down-regulated in colorectal cancer.International journal of experimental pathology · 2023Article
- Targeting IGF2BP3 in Cancer.International journal of molecular sciences · 2023Review
- A novel tumour enhancer function of Insulin-like growth factor II mRNA-binding protein 3 in colorectal cancer.Cell death & disease · 2023Article
- Association between the ELAVL1 gene single nucleotide polymorphisms and the Genetic Susceptibility to cervical cancer by high resolution melting in a Tunisian population.Molecular biology reports · 2023Article
- Solute Carrier Family 27 Member 6 (SLC27A6) Possibly Promotes the Proliferation of Papillary Thyroid Cancer by Regulating c-MYC.Biochemical genetics · 2022Article
- Identification and verification of the ferroptosis- and pyroptosis-associated prognostic signature for low-grade glioma.Bosnian journal of basic medical sciences · 2022Article
- Role of m6A writers, erasers and readers in cancer.Experimental hematology & oncology · 2022Review
- Abnormal Expression of N6-Methyladenosine RNA Methylation Regulator IGF2BP3 in Colon Cancer Predicts a Poor Prognosis.Disease markers · 2022Article
- IGF2BP3 promotes progression of gallbladder carcinoma by stabilizing KLK5 mRNA in NFrontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The expression of RNA-binding proteins (RBPs) is dysregulated in colorectal cancer (CRC) and in other types of cancer. Among the RBPs, the insulin-like growth factor-2 messenger RNA binding protein (IGF2BP1-3) family is involved in the development of the colon and the progression of CRC. However, the regulation of mRNA fate by IGF2BP3 in CRC remains less well understood. Here, we show that IGF2BP3 interacts with ELAVL1 to coregulate a cohort of genes involved in the cell cycle and cell proliferation. Mechanistically, recognition of these mRNAs by the IGF2BP3/ELAVL1 complex leads to prolonged half-lives of the mRNA molecules and increased expression of the target genes, thereby driving CRC cell proliferation. Interestingly, knockdown of either IGF2BP3 or ELAVL1 impairs the IGF2BP3/ELAVL1 complex-enhanced mRNA stability, suggesting a functional interdependency between IGF2BP3 and ELAVL1 in CRC. Our findings reveal the molecular mechanism by which IGF2BP3 regulates mRNA stability and identify the cooperativity of the IGF2BP3/ELAVL1 complex as a novel therapeutic target in CRC.
Indexed as
Identifiers
32905413PMC7471344W3085963678What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.